blog - Page 2 of 3

Hemanext AABB 2022

Hemanext is a privately held medical technology company dedicated to improving the quality, safety, efficacy, and cost of transfusion therapy. The company’s research and development efforts center on the study of hypoxically stored red blood cells (RBCs). Learn More...

Hemanext successfully closes series a equity funding round, bringing total raised to more than $100 million

Press Release

Leading Blood Storage Innovator Expanded Series A Round to Accommodate Interest from Noted Private Investors Transformative Technology CE Marked for Sale in European Markets in April 2021; Company Will Submit for FDA Authorization Later This Year LEXINGTON, Mass.,...

Hemanext Announces that Hypoxic Blood Storage Study has been Recognized as Best Original Research Paper by AABB

Hemanext, Press Release

Research supports Hemanext’s aim to improve clinical outcomes of transfusion recipients with its innovative red blood cell processing and storage system. LEXINGTON, Mass., September 21, 2021, PR NEWSWIRE – Hemanext Inc. (“Hemanext” or the...

Hemanext^® Inc. Receives CE Mark Certification for Innovative Red Blood Cell (RBC) Processing & Storage System

CE Mark

Company to launch Hemanext ONE® RBC Processing and Storage System in select European markets in 2021, with wider distribution in Europe and the Americas in 2022 and future years LEXINGTON, Mass., Apr 13, 2021, PRNEWSWIRE – Hemanext Inc ., a privately held US-based...

Hemanext Announces Appointment of Paul M. Ness, M.D., to Board of Directors

Hemanext, Press Release

Senior Director of Transfusion Medicine at Johns Hopkins University Brings Global Experience in Transfusion Medicine and Research Company Recently Received CE Mark Certification for Innovative Red Blood Cell Processing and Storage System LEXINGTON, Mass., Aug 3, 2021,...

Hemanext Partners with Sickle Cell 101 to Sponsor Sickle Cell Education

Hemanext, Press Release

Sickle Cell Disease (SCD) Affects Over 20M Worldwide, including 100K Americans1,2 LEXINGTON, MA and SAN FRANCISCO, CA – Jul 28, 2021 – Hemanext Inc. a privately held, US-based medical technology company dedicated to improving the quality, safety, efficacy, and cost of...

Sickle Cell Disease Association of America, Inc. Launches New Educational Materials to Support Children’s Blood Transfusion

SCDAA

Sickle Cell Disease Association of America, Inc. Launches New Educational Materials to Support Children’s Blood Transfusion Pictorial booklet for children and companion brochure for caregivers sponsored by Hemanext HANOVER, Md. and LEXINGTON, Mass., April 1, 2021...

Connect with Hemanext at ISBT 2020

Events, Hemanext, ISBT2020, News

Connect with Hemanext virtual booth at the 36th International Congress of Society of Blood Transfusions (ISBT). Learn about: Blood quality and potential impact on transfusion outcomes Potential benefits of hypoxic storage Hemanext’s vision to create a world with...

Celebrating Jimmy Devarie Conde (1969 – 2020)

Hemanext, News

In Commemoration of Jimmy Devarie Conde (1969 – 2020) With deep sadness, we inform you of the sudden passing on November 5th of Jimmy Devarie, Plant Manager of the NHS Manufacturing facility. Jimmy was admired, respected, and loved by his team and colleagues here at...

Publications

View a compilation of Hemanext publications from a wide variety of studies, abstracts, and posters that are categorized by various aspects of blood quality. Also explore other publications in related field of research. Current Thinking on Blood Quality Ours: Yoshida...

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

YOU ARE ABOUT TO EXIT A US HEMANEXT CORPORATE WEBSITE FOR A GLOBAL HEMANEXT ONE PRODUCT WEBSITE

Recent Posts